Can CAR-T Be Optimized for Multiple Myeloma?
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Multiple Myeloma
Response-Adapted Intensification in Multiple Myeloma After Suboptimal Response to Induction
Patients who received intensification treatment experienced longer progression-free survival compared with patients receiving maintenance treatment.
Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma
Patients receiving the 3-drug treatment experienced increasing rates of complete response and measurable residual disease from induction through consolidation.
Lenalidomide Delays Progression in Smoldering Multiple Myeloma
Progression-free survival significantly longer with lenalidomide compared with observation
Hematologic Scoring System Predicts Survival in Multiple Myeloma
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.
Racial Disparities Affect Myeloma Treatment, Though Survival May Be Similar
Time to initiation of therapy was significantly longer for black and Hispanic patients compared with white patients.
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
Defects in Primary Hemostasis May Cause Bleeding in Multiple Myeloma
Prolonged closure time and defects in von Willebrand factor were identified as risk factors for bleeding complications patients with multiple myeloma.
Subgroup Analysis of Carfilzomib for Relapsed or Refractory Multiple Myeloma in Asian Patients
Researchers conducted a subgroup analysis of Asian patients with relapsed or refractory multiple myeloma who received carfilzomib in 2 phase 3 clinical trials.
CAR-T Therapy May Be More Effective When Administered Earlier in the Multiple Myeloma Treatment Continuum
A critical step in the preparation of autologous CAR-T therapy is the ex vivo proliferation of T cells from samples obtained from leukapheresis.
